Cantor Fitzgerald initiated coverage of Rocket Pharmaceuticals with an Overweight rating and $65 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RCKT:
- Rocket says FDA accepts BLA with priority review for RP-L201 to treat LAD-I
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today
- Rocket Pharmaceuticals price target lowered to $53 from $60 at Needham
- Rocket Pharmaceuticals 7.81M share Spot Secondary priced at $16.00
